Dr. Abramovits is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5310 Harvest Hill Rd
#160
Dallas, TX 75230Phone+1 972-661-2729Fax+1 972-661-0227
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1977 - 1979
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1976 - 1977
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
- University of Texas Health Science Center at HoustonInternship, Transitional Year, 1973 - 1974
- Central University of VenezuelaClass of 1972
Certifications & Licensure
- TX State Medical License 1989 - 2025
- OK State Medical License 1976 - 1990
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Compulink Advantage EHR, Compulink, 2012
Clinical Trials
- Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
- Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsSpesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, plac...Robert Bissonnette, William Abramovits, Étienne Saint-Cyr Proulx, Patricia Lee, Emma Guttman-Yassky
Journal of the European Academy of Dermatology and Venereology. 2023-03-01 - Seborrheic Keratosis: A Not So Humble Skin Lesion.William Abramovits, Sijil Patel, Kimberly Dawn Vincent, Aditya Gupta
Skinmed. 2023-01-01 - 16 citationsPharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents.Robert Sidbury, Sady Alpizar, Vivian Laquer, Sunil Dhawan, William Abramovits
Dermatology and Therapy. 2022-03-01
Journal Articles
- Conceptual Issues in Dermatology and Medicine: Where Do Nonphysician Practitioners Rightfully Belong—a Dermatologist’s PerspectiveWilliam Abramovits, MD, ScienceDirect
Press Mentions
- CommentaryJanuary 3rd, 2018
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: